Publications by authors named "C L Duvall"
Objective: The study objective was to assess longitudinal postoperative health-related quality of life among patients with adult congenital heart disease facilitated by a novel electronic medical record-based patient-reported outcomes follow-up platform.
Methods: From January 2022 to October 2023, 559 patients with adult congenital heart disease underwent cardiac surgery; 491 (88%) completed a 23-element health-related quality of life questionnaire covering 3 domains (physical, mental, and social) yielding 911 assessments. Automated questionnaires via electronic medical record were sent at 7 days preoperatively and postoperatively at 1, 3, 6, and 12 months.
Objective: Investigational cell therapies have been developed as disease-modifying agents for the treatment of osteoarthritis (OA), including those that inducibly respond to inflammatory factors driving OA progression. However, dysregulated inflammatory cascades do not specifically signify the presence of OA. Here, we deploy a synthetic receptor platform that regulates cell behaviors in an arthritis-specific fashion to confine transgene expression to sites of cartilage degeneration.
View Article and Find Full Text PDFArticle Synopsis
- - Cas9 and its fusions are powerful tools for genetic editing, with modifications enabling single base editing and targeted genome manipulation using catalytically dead variants.
- - A panel of nanobodies was created, sourced from an alpaca, targeting specific regions (epitopes) on Streptococcus pyogenes Cas9, capable of recognizing both Cas9 and RNA-bound Cas9 without hindering its DNA cleavage function.
- - The study provides detailed sequences of these nanobodies and accompanying biochemical data, allowing other scientists to utilize these reagents in their research.
Article Synopsis
- siRNA therapeutics have great potential for treating cancer, but effective delivery methods that reduce toxicity while promoting rapid cellular uptake have been difficult to develop.
- Our team created an innovative siRNA conjugate platform named "siRNA-L," which uses natural albumin in the bloodstream for targeted delivery to tumors without relying on traditional lipid or polymer methods.
- To enhance the effectiveness of siRNA-L, we synthesized a new conjugate called siRNA-CQ-L that incorporates chloroquine for better endosomal escape and higher gene silencing efficiency, showing no significant toxicity in mice while improving delivery and retention in cancer cells.
This work establishes the design of a fully synthetic, shear-thinning hydrogel platform that is injectable and can isolate engineered, allogeneic cell therapies from the host. We utilized RAFT to generate a library of linear random copolymers of N,N-dimethylacrylamide (DMA) and 2-vinyl-4,4-dimethyl azlactone (VDMA) with variable mol% VDMA and degree of polymerization. Poly(DMA-co-VDMA) copolymers were subsequently modified with either adamantane (Ad) or β-cyclodextrin (Cd) through amine-reactive VDMA to prepare hydrogel precursor macromers containing complementary guest-host pairing pendant groups that, when mixed, form shear-thinning hydrogels.
View Article and Find Full Text PDF